The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas / Juan Carlos Restrepo Gutiérrez  

Público ISBD Título : The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas Tipo de documento : documento electrónico Autores : Juan Carlos Restrepo Gutiérrez, Fecha de publicación : 2022 Títulos uniformes : The Lancet Gastroenterology and Hepatology Idioma : Inglés (eng) Resumen : Non-alcoholic fatty liver disease (NAFLD) affects 20–25% of the general population and is associated with morbidity, increased mortality, and elevated health-care costs. Most NAFLD risk factors are modifiable and, therefore, potentially amenable to being reduced by public health policies. To date, there is no information about NAFLD-related public health policies in the Americas. In this study, we analysed data from 17 American countries and found that none have established national public health policies to decrease NAFLD-related burden. There is notable heterogeneity in the existence of public health policies to prevent NAFLD-related conditions. The most common public health policies were related to diabetes (15 [88%] countries), hypertension (14 [82%] countries), cardiovascular diseases (14 [82%] countries), obesity (nine [53%] countries), and dyslipidaemia (six [35%] of countries). Only seven (41%) countries had a registry of the burden of NAFLD, and efforts to raise awareness in the Americas were scarce. The implementation of public health policies are urgently needed in the Americas to decrease the burden of NAFLD. Mención de responsabilidad : Luis Antonio Díaz, MD, Eduardo Fuentes-López, PhD, Gustavo Ayares, MD, Francisco Idalsoaga, MD, Jorge Arnold, MD, Andrea Márquez-Lomas, MD, Carolina A Ramírez, MD, María Paz Medel, MD, Francisca Viñuela, BS, Lucas Lacalle, BS, Juan Pablo Roblero, MD, Prof Catterina Ferreccio, PhD, Mariana Lazo, MD, Mayur Brahmania, MD, Prof Ashwani K Singal, MD, Melisa Dirchwolf, MD, Prof Nahum Méndez-Sánchez, MD, Norberto Chavez-Tapia, MD, Patricia Guerra, MD, Juan Carlos Restrepo, MD, Claudia P Oliveira, MD, Julissa Lombardo, MD, Abel Sánchez, MD, Martín Elizondo, MD, Prof Martín Tagle, MD, Martín Padilla, MD, Marco Sánchez, MD, Enrique Carrera, MD, Marcos Girala, MD, Omega Chery, MD, Marlen Castellanos-Fernández, MD, Francisco Barrera, MD, Prof Jeffrey V Lazarus, PhD, Prof Patrick S Kamath, MD, Prof Ramon Bataller, MD, Prof Marco Arrese, MD, Juan Pablo Arab, MD Referencia : Lancet Gastroenterol Hepatol. 2022 Jun;7(6):552-559. DOI (Digital Object Identifier) : 10.1016/S2468-1253(22)00008-5 PMID : 35430032 En línea : https://linkinghub.elsevier.com/retrieve/pii/S2468125322000085 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6019 The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas [documento electrónico] / Juan Carlos Restrepo Gutiérrez,  . - 2022. Obra : The Lancet Gastroenterology and Hepatology Idioma : Inglés (eng) Resumen : Non-alcoholic fatty liver disease (NAFLD) affects 20–25% of the general population and is associated with morbidity, increased mortality, and elevated health-care costs. Most NAFLD risk factors are modifiable and, therefore, potentially amenable to being reduced by public health policies. To date, there is no information about NAFLD-related public health policies in the Americas. In this study, we analysed data from 17 American countries and found that none have established national public health policies to decrease NAFLD-related burden. There is notable heterogeneity in the existence of public health policies to prevent NAFLD-related conditions. The most common public health policies were related to diabetes (15 [88%] countries), hypertension (14 [82%] countries), cardiovascular diseases (14 [82%] countries), obesity (nine [53%] countries), and dyslipidaemia (six [35%] of countries). Only seven (41%) countries had a registry of the burden of NAFLD, and efforts to raise awareness in the Americas were scarce. The implementation of public health policies are urgently needed in the Americas to decrease the burden of NAFLD. Mención de responsabilidad : Luis Antonio Díaz, MD, Eduardo Fuentes-López, PhD, Gustavo Ayares, MD, Francisco Idalsoaga, MD, Jorge Arnold, MD, Andrea Márquez-Lomas, MD, Carolina A Ramírez, MD, María Paz Medel, MD, Francisca Viñuela, BS, Lucas Lacalle, BS, Juan Pablo Roblero, MD, Prof Catterina Ferreccio, PhD, Mariana Lazo, MD, Mayur Brahmania, MD, Prof Ashwani K Singal, MD, Melisa Dirchwolf, MD, Prof Nahum Méndez-Sánchez, MD, Norberto Chavez-Tapia, MD, Patricia Guerra, MD, Juan Carlos Restrepo, MD, Claudia P Oliveira, MD, Julissa Lombardo, MD, Abel Sánchez, MD, Martín Elizondo, MD, Prof Martín Tagle, MD, Martín Padilla, MD, Marco Sánchez, MD, Enrique Carrera, MD, Marcos Girala, MD, Omega Chery, MD, Marlen Castellanos-Fernández, MD, Francisco Barrera, MD, Prof Jeffrey V Lazarus, PhD, Prof Patrick S Kamath, MD, Prof Ramon Bataller, MD, Prof Marco Arrese, MD, Juan Pablo Arab, MD Referencia : Lancet Gastroenterol Hepatol. 2022 Jun;7(6):552-559. DOI (Digital Object Identifier) : 10.1016/S2468-1253(22)00008-5 PMID : 35430032 En línea : https://linkinghub.elsevier.com/retrieve/pii/S2468125322000085 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6019

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001858	AC-2022-025	Archivo digital	Producción Científica	Artículos científicos	Disponible

The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease / Juan Carlos Restrepo Gutiérrez  

Público ISBD Título : The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease Tipo de documento : documento electrónico Autores : Juan Carlos Restrepo Gutiérrez, Fecha de publicación : 2021 Títulos uniformes : The Lancet Gastroenterology and Hepatology Idioma : Inglés (eng) Resumen : The Latin American Association for the Study of the Liver (Asociación Latinoamericana para el Estudio del Hígado; ALEH) represents liver professionals in Latin America with the mission of promoting liver health and quality patient care by advancing the science and practice of hepatology and contributing to the development of a regional health policy framework. Fatty liver disease associated with metabolic dysfunction is of specific concern in the ALEH region, where its prevalence is one of the highest globally, second only to the Middle East. A recent consensus from an international panel recommended a new definition of fatty liver disease associated with metabolic dysfunction, including a shift in name from non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD), and adoption of a set of positive criteria to diagnose the disease, independent of alcohol intake or other liver diseases. Given, the importance of this proposal, ALEH invited leading members of regional nations to come to a consensus on it from a local perspective. We reached a consensus to endorse the proposal that the disease should be renamed as MAFLD and that the disease should be diagnosed by the proposed simple and easily applicable criteria. We expect that this change in nosology will result in improvements in disease awareness and in advances in scientific, economic, public health, political, and regulatory aspects of the disease. Mención de responsabilidad : Nahum Mendez-Sanchez, Marco Arrese, Adrian Gadano, Claudia P Oliveira, Eduardo Fassio, Juan Pablo Arab, Norberto C Chávez-Tapia, Melisa Dirchwolf, Aldo Torre, Ezequiel Ridruejo, Helma Pinchemel-Cotrim, Marlen Ivón Castellanos Fernández, Misael Uribe, Marcos Girala, Javier Diaz-Ferrer, Juan C Restrepo, Martín Padilla-Machaca, Lucy Dagher, Manuel Gatica, Blanca Olaechea, Mario G Pessôa, Marcelo Silva Referencia : Lancet Gastroenterol Hepatol. 2021 Jan;6(1):65-72. DOI (Digital Object Identifier) : 10.1016/S2468-1253(20)30340-X PMID : 33181118 En línea : https://linkinghub.elsevier.com/retrieve/pii/S246812532030340X Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5729 The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease [documento electrónico] / Juan Carlos Restrepo Gutiérrez,  . - 2021. Obra : The Lancet Gastroenterology and Hepatology Idioma : Inglés (eng) Resumen : The Latin American Association for the Study of the Liver (Asociación Latinoamericana para el Estudio del Hígado; ALEH) represents liver professionals in Latin America with the mission of promoting liver health and quality patient care by advancing the science and practice of hepatology and contributing to the development of a regional health policy framework. Fatty liver disease associated with metabolic dysfunction is of specific concern in the ALEH region, where its prevalence is one of the highest globally, second only to the Middle East. A recent consensus from an international panel recommended a new definition of fatty liver disease associated with metabolic dysfunction, including a shift in name from non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD), and adoption of a set of positive criteria to diagnose the disease, independent of alcohol intake or other liver diseases. Given, the importance of this proposal, ALEH invited leading members of regional nations to come to a consensus on it from a local perspective. We reached a consensus to endorse the proposal that the disease should be renamed as MAFLD and that the disease should be diagnosed by the proposed simple and easily applicable criteria. We expect that this change in nosology will result in improvements in disease awareness and in advances in scientific, economic, public health, political, and regulatory aspects of the disease. Mención de responsabilidad : Nahum Mendez-Sanchez, Marco Arrese, Adrian Gadano, Claudia P Oliveira, Eduardo Fassio, Juan Pablo Arab, Norberto C Chávez-Tapia, Melisa Dirchwolf, Aldo Torre, Ezequiel Ridruejo, Helma Pinchemel-Cotrim, Marlen Ivón Castellanos Fernández, Misael Uribe, Marcos Girala, Javier Diaz-Ferrer, Juan C Restrepo, Martín Padilla-Machaca, Lucy Dagher, Manuel Gatica, Blanca Olaechea, Mario G Pessôa, Marcelo Silva Referencia : Lancet Gastroenterol Hepatol. 2021 Jan;6(1):65-72. DOI (Digital Object Identifier) : 10.1016/S2468-1253(20)30340-X PMID : 33181118 En línea : https://linkinghub.elsevier.com/retrieve/pii/S246812532030340X Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5729

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001592	AC-2020-098	Archivo digital	Producción Científica	Artículos científicos	Disponible

Pseudomembranous colitis from cytomegalovirus infection / Juan Camilo Pérez Cadavid  

Público ISBD Título : Pseudomembranous colitis from cytomegalovirus infection Tipo de documento : documento electrónico Autores : Juan Camilo Pérez Cadavid, Fecha de publicación : 2017 Títulos uniformes : The Lancet Gastroenterology and Hepatology Idioma : Inglés (eng) Mención de responsabilidad : Dayana Sylva, Pablo Villa, Cristian García, Juan Camilo Pérez, Carlos Andrés Agudelo Referencia : Lancet Gastroenterol Hepatol. 2017 May;2(5):384. DOI (Digital Object Identifier) : 10.1016/S2468-1253(17)30044-4 PMID : 28397703 En línea : https://linkinghub.elsevier.com/retrieve/pii/S2468125317300444 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4084 Pseudomembranous colitis from cytomegalovirus infection [documento electrónico] / Juan Camilo Pérez Cadavid,  . - 2017. Obra : The Lancet Gastroenterology and Hepatology Idioma : Inglés (eng) Mención de responsabilidad : Dayana Sylva, Pablo Villa, Cristian García, Juan Camilo Pérez, Carlos Andrés Agudelo Referencia : Lancet Gastroenterol Hepatol. 2017 May;2(5):384. DOI (Digital Object Identifier) : 10.1016/S2468-1253(17)30044-4 PMID : 28397703 En línea : https://linkinghub.elsevier.com/retrieve/pii/S2468125317300444 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4084

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000693	AC-2017-082	Archivo digital	Producción Científica	Artículos científicos	Disponible

---

1 (1 - 3 / 3) Por página: 25 50 100 200